Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilin.

[1]  Gregory W. Kauffman,et al.  Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators. , 2014, Journal of medicinal chemistry.

[2]  Shannon Rumfelt,et al.  Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease. , 2013, Bioorganic & medicinal chemistry letters.

[3]  Gregory W. Kauffman,et al.  Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012 , 2013, Expert opinion on therapeutic patents.

[4]  G. Macdonald,et al.  Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators. , 2013, Bioorganic & medicinal chemistry letters.

[5]  Douglas S. Johnson,et al.  Development and mechanism of γ-secretase modulators for Alzheimer's disease. , 2013, Biochemistry.

[6]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[7]  K. Bales,et al.  γ-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin* , 2013, The Journal of Biological Chemistry.

[8]  Christopher W. am Ende,et al.  Synthesis of pyridopyrazine-1,6-diones from 6-hydroxypicolinic acids via a one-pot coupling/cyclization reaction. , 2013, Organic letters.

[9]  K. Blennow,et al.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[10]  R. Berman,et al.  Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men , 2012, Clinical Drug Investigation.

[11]  Feng Wang,et al.  BMS-708,163 targets presenilin and lacks notch-sparing activity. , 2012, Biochemistry.

[12]  Gregory W. Kauffman,et al.  Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators. , 2012, Bioorganic & medicinal chemistry letters.

[13]  Y. Shitaka,et al.  Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.

[14]  Lynn A. Hyde,et al.  Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo. , 2012, Journal of medicinal chemistry.

[15]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[16]  G. Logroscino,et al.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? , 2011, Expert opinion on investigational drugs.

[17]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[18]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[19]  Tanya L Hay,et al.  Modulation of the Partition Coefficient between Octanol and Buffer at pH 7.4 and pKa to Achieve the Optimum Balance of Blood Clearance and Volume of Distribution for a Series of Tetrahydropyran Histamine Type 3 Receptor Antagonists , 2009, Drug Metabolism and Disposition.

[20]  Dafydd R Owen,et al.  Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[22]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[23]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[24]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[25]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[26]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[27]  A. Hall,et al.  γ-Secretase modulators: current status and future directions. , 2014, Progress in medicinal chemistry.

[28]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.